Safety and Efficacy of HL Tablet in Non-alcoholic Fatty Liver Disease Patients

Inclusion Criteria: 1. Age between 19 and 75 2. Non-alcoholic fatty liver disease patient * Diagnosed by abdomen ultrasonic examination * Non-drinker (alcohol intake per week : female-under 140g, male-under 210g) 3. ALT or AST higher than normal range (not over 4 times normal range) 4. Voluntary agreement and enrollment Exclusion Criteria: 1. The ratio of AST/ALT over 2 2. Type I diabetes mellitus patient 3. Any dysfunction of liver besides non-alcoholic fatty liver disease 4. Alcoholic fatty liver disease patient or heavy drinker 5. Prior treatment with any medicine which affects the treatment of non-alcoholic fatty liver disease within 3 months 6. Patient taking any product which affects the BMI or hyperlipidemia 7. Any dyscrasia that investigator considers not to appropriate for this study 8. Bariatric surgery within 6 months 9. Any disease which is able to change the distribution of cytokines 10. Any treatment that affects liver functions within 1 month 11. Participation in other clinical trials within 3 months 12. Person who can not use MRS 13. Pregnancy or breast-feeding 14. Fertile women who do not use contraception 15. Sensitive to the investigational product 16. Any conditions that the investigator considers not to appropriate for this study